IQVIA Holdings Inc. (IQV)
USD 146.15
(2.05%)
USD 146.15
(2.05%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.97 Billion USD | 15.73% |
| 2022 | 1.79 Billion USD | 29.15% |
| 2021 | 1.39 Billion USD | 90.56% |
| 2020 | 731 Million USD | -5.92% |
| 2019 | 777 Million USD | 4.86% |
| 2018 | 741 Million USD | 3.06% |
| 2017 | 719 Million USD | 11.99% |
| 2016 | 642 Million USD | -0.71% |
| 2015 | 646.61 Million USD | 9.52% |
| 2014 | 590.39 Million USD | 27.7% |
| 2013 | 462.33 Million USD | 16.62% |
| 2012 | 396.43 Million USD | 14.83% |
| 2011 | 345.25 Million USD | -12.6% |
| 2010 | 395 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 524 Million USD | -6.26% |
| 2024 Q2 | 548 Million USD | 4.58% |
| 2024 Q3 | 550 Million USD | 0.36% |
| 2023 Q4 | 559 Million USD | 16.22% |
| 2023 Q3 | 481 Million USD | -8.21% |
| 2023 FY | 2.08 Billion USD | 15.73% |
| 2023 Q1 | 471 Million USD | 24.27% |
| 2023 Q2 | 524 Million USD | 11.25% |
| 2022 Q4 | 379 Million USD | -19.7% |
| 2022 Q3 | 472 Million USD | 4.19% |
| 2022 Q2 | 453 Million USD | -8.48% |
| 2022 FY | 1.79 Billion USD | 29.15% |
| 2022 Q1 | 495 Million USD | 6.91% |
| 2021 Q1 | 342 Million USD | 18.34% |
| 2021 Q2 | 286 Million USD | -16.37% |
| 2021 Q3 | 302 Million USD | 5.59% |
| 2021 Q4 | 463 Million USD | 53.31% |
| 2021 FY | 1.39 Billion USD | 90.56% |
| 2020 Q4 | 289 Million USD | 54.55% |
| 2020 Q3 | 187 Million USD | 201.61% |
| 2020 Q2 | 62 Million USD | -67.88% |
| 2020 Q1 | 193 Million USD | 16.27% |
| 2020 FY | 731 Million USD | -5.92% |
| 2019 Q2 | 197 Million USD | -6.19% |
| 2019 FY | 777 Million USD | 4.86% |
| 2019 Q4 | 166 Million USD | -18.63% |
| 2019 Q3 | 204 Million USD | 3.55% |
| 2019 Q1 | 210 Million USD | 1.45% |
| 2018 Q4 | 207 Million USD | 14.36% |
| 2018 Q2 | 170 Million USD | -7.1% |
| 2018 FY | 741 Million USD | 3.06% |
| 2018 Q1 | 183 Million USD | -9.85% |
| 2018 Q3 | 181 Million USD | 6.47% |
| 2017 Q2 | 151 Million USD | -10.12% |
| 2017 Q4 | 203 Million USD | 3.05% |
| 2017 Q1 | 168 Million USD | 16.67% |
| 2017 Q3 | 197 Million USD | 30.46% |
| 2017 FY | 719 Million USD | 11.99% |
| 2016 FY | 642 Million USD | -0.71% |
| 2016 Q3 | 167.77 Million USD | 11.3% |
| 2016 Q2 | 150.74 Million USD | -15.69% |
| 2016 Q1 | 178.79 Million USD | 0.46% |
| 2016 Q4 | 144 Million USD | -14.17% |
| 2015 Q1 | 143.21 Million USD | -9.89% |
| 2015 Q4 | 177.98 Million USD | 6.56% |
| 2015 Q3 | 167.02 Million USD | 5.45% |
| 2015 Q2 | 158.38 Million USD | 10.59% |
| 2015 FY | 646.61 Million USD | 9.52% |
| 2014 Q3 | 149.14 Million USD | 5.77% |
| 2014 Q2 | 141 Million USD | -0.22% |
| 2014 Q1 | 141.31 Million USD | 11.26% |
| 2014 FY | 590.39 Million USD | 27.7% |
| 2014 Q4 | 158.93 Million USD | 6.56% |
| 2013 Q4 | 127.01 Million USD | 1.4% |
| 2013 Q1 | 115.16 Million USD | 21.96% |
| 2013 FY | 462.33 Million USD | 16.62% |
| 2013 Q2 | 94.89 Million USD | -17.6% |
| 2013 Q3 | 125.25 Million USD | 31.99% |
| 2012 FY | 396.43 Million USD | 14.83% |
| 2012 Q1 | 91.98 Million USD | 0.0% |
| 2012 Q4 | 94.42 Million USD | -13.48% |
| 2012 Q2 | 100.88 Million USD | 9.67% |
| 2012 Q3 | 109.13 Million USD | 8.18% |
| 2011 FY | 345.25 Million USD | -12.6% |
| 2010 FY | 395 Million USD | 0.0% |
| 2001 Q3 | 472 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Agilent Technologies, Inc. | 1.35 Billion USD | -46.444% |
| Charles River Laboratories International, Inc. | 617.26 Million USD | -220.286% |
| Quest Diagnostics Incorporated | 1.26 Billion USD | -56.656% |
| Danaher Corporation | 5.2 Billion USD | 61.995% |
| Enzo Biochem, Inc. | -9.81 Million USD | 20238.535% |
| Laboratory Corporation of America Holdings | 725.6 Million USD | -172.464% |
| Mettler-Toledo International Inc. | 1.15 Billion USD | -71.63% |
| Qiagen N.V. | 445.24 Million USD | -344.023% |
| Revvity, Inc. | 300.56 Million USD | -557.768% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 71.177% |
| Waters Corporation | 817.67 Million USD | -141.783% |